TERT and neoplasm: For this reason, we propose that a systematic assessment of CD4 T cell immunity to TERT in circulating lymphocytes could be used to predict the response to immune checkpoint inhibitors, even though the ultimate anti-tumor effector function may be against tumor antigens other than TERT, for example neoantigens.